Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-06-18
2010-02-16
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07662778
ABSTRACT:
HDAC inhibitor of the general formula (1) exhibits strong inhibitory activity against various subtype HDACs. The compound is useful as a medicinal agent for the treatment or prevention of HDAC 1, 4 and 6-related diseases. There is further provided a process for producing the compound which is capable of readily synthesizing various types of compounds and is promising in the contribution to the development of HDAC inhibitor having novel properties, etc.
REFERENCES:
patent: 5922837 (1999-07-01), Meinke et al.
patent: 6399568 (2002-06-01), Nishino et al.
patent: 7488712 (2009-02-01), Yoshida
patent: 2002/0120099 (2002-08-01), Nishino et al.
patent: 2003/0078369 (2003-04-01), Meinke et al.
patent: 2 317 003 (2000-08-01), None
patent: 1 010 705 (2000-06-01), None
patent: 1 174 438 (2002-01-01), None
patent: 11-130795 (1999-05-01), None
patent: EP 1010705 (2000-06-01), None
patent: 2000-256397 (2000-09-01), None
patent: 2001-316283 (2001-11-01), None
patent: 2002-527449 (2002-08-01), None
patent: 2003-505417 (2003-02-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/52033 (2000-09-01), None
patent: WO 01/07042 (2001-02-01), None
patent: WO 03/057722 (2003-07-01), None
patent: WO 03/070754 (2003-08-01), None
Saito A, “A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors,” Proc NatI Acad Sci U S A. Apr. 13, 1999;96(8):4592-7.
Bernhard et al., “Interaction between dexamethasone and butyrate in apoptosis induction: non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line,”Cell Death Diff., 1999, 6:609-617.
Boivin et al., “Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells,”Anti-Cancer Drugs, 2002, 13:869-874.
Cameron et al., “Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer,”Nature Genet., 1999, 21:103-107.
Chen et al., “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase,”Proc. Natl. Acad. Sci. USA, 1997, 94:5798-5803.
Coffey et al., “The Histone Deacetylase Inhibitor, CBHA, Inhibits Growth of Human Neuroblastoma Xenografts in Vivo, Alone and Synergistically withAll-TransRetinoic Acid,”Cancer Res., 2001, 61:3591-3594.
Colletti et al., “Design and synthesis of histone deacetylase inhibitors: the development of apicidin transition state analogs,” Tetrahedron Lett., 2000, 41:7837-7841.
Colletti et al., “Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure-Activity Relationships of Apicidin. Part 2,”Bioorg. Med. Chem. Lett., 2001, 11:113-117.
Darkin-Rattray et al., “Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase,”Proc. Natl. Acad. Sci. USA, 1996, 93:13143-13147.
De Schepper et al., “Inhibition of Histone Deacetylases by Chlamydocin Induces Apoptosis and Proteasome-Mediated Degradation of Survivin,”J. Pharmacol. Exp. Ther., 2003, 304(2):881-888.
Dhordain et al., “Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein,”Proc. Natl. Acad. Sci. USA, 1997, 94:10762-10767.
Dion et al., “Amplification of Recombinant Adenoviral Transgene Products Occurs by Inhibition of Histone Deacetylase,”Virology, 1997, 231:201-209.
Ferrara et al., “Histone Deacetylase-targeted Treatment Restores Retinoic Acid Signaling and Differentiation in Acute Myeloid Leukemia,”Cancer Res., 2001, 61:2-7.
Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,”Nature, 1999, 401:188-193.
Fischle et al., “A New Family of Human Histone Deacetylases Related toSaccharomyces cerevisiaeHDA1p,”J. Biol. Chem., 1999, 274(17):11713-11720.
Frey et al., “Trifluoromethyl Ketones as Inhibitors of Histone Deacetylase,”Bioorg. Med. Chem. Lett., 2002, 12:3443-3447.
Furumai et al., “Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin,”Proc. Natl. Acad. Sci. USA, 2001, 98(1):87-92.
Furumai et al., “FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases,”Cancer Res., 2002, 62:4916-4921.
Göttlicher et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,”EMBO J., 2001, 20(24):6969-6978.
Grignani et al., “Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia,”Nature, 1998, 391:815-818.
He et al., “Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL,”Nature Genet., 1998, 18:126-135.
Hoshi et al., “Activation of a Ca2+-inhibitable Protein Kinase That Phosphorylates Microtubule—associated Protein 2 in Vitro by Growth Factors, Phorbol Esters, and Serum in Quiescent Cultured Human Fibroblasts,”J. Biol. Chem., 1988, 263(11):5396-5401.
Hoshikawa et al., “Expression of Differentiation-related Markers in Teratocarcinoma Cells via Histone Hyperacetylation by Trichostatin A,”Agric. Biol. Chem., 1991, 55(6):1491-1495.
Hubbert et al., “HDAC6 is a microtubule-associated deacetylase,”Nature, 2002, 417:455-458.
Inokoshi et al., “Neuronal Differentiation of Neuro 2a Cells by Inhibitors of Cell Cycle Progression, Trichostatin A and Butyrolactone I,”Biochem. Biophys. Res. Commun., 1999, 256(2):372-376.
Ito et al., “p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2,”EMBO J., 2001, 20(6):1331-1340.
Jose et al., “Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from α-tubulin sequence,”Bioorg. Med. Chem., 2004, 12:1351-1356.
Juan et al., “Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation,”J. Biol. Chem., 2000, 275(27):20436-20443.
Kim et al., “Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes,”Nature Med., 2001, 7(4):437-443.
Kim et al., “Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase,”Oncogene, 1999, 18:2461-2470.
Komatsu et al., “Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity,”Cancer Res., 2001, 61:4459-4466.
Kwon et al., “Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis,”Int. J. Cancer, 2002, 97:290-296.
Li et al., “Causal Relationship between the Loss ofRUNX3Expression and Gastric Cancer,”Cell, 2002, 109:113-124.
Lin et al., “Role of the histone deacetylase complex in acute promyelocytic leukaemia,”Nature, 1998, 391:811-814.
Liu et al., “Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion,”Cancer Res., 2003, 63:3069-3072.
Marks et al., “Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells,”J. Natl. Cancer Inst., 2000, 92(15):1210-1216.
Matsuyama et al., “In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation,”EMBO J., 2002, 21(24):6820-6831.
McCampbell et al., “Histone deacetylase inhibitors reduce polyglutamine toxicity,”Proc. Natl. Acad. Sci. USA, 2001, 98(26):15179-15184.
McKinsey et al., “Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation,”Nature, 2000, 408:106-111.
Meinke et al., “Synthesis of side chain modified apicidin derivatives: potent mechanism-based histone deacetylase inhibitors,”Tetrahedron Lett., 2000, 41:7831-7835.
Minucci et al., “A histone deacetylase inhibitor potentiat
Nishino Norikazu
Yoshida Minoru
Fish & Richardson P.C.
Heard Thomas S
Riken
Tsang Cecilia
LandOfFree
Histone deacetylase inhibitor and process for producing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylase inhibitor and process for producing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitor and process for producing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180430